弊社は、バイオ革命によって急速に発展し始めている再生医療分野において、体性幹細胞再生医薬品/iPSC再生医薬品の研究開発を行っているバイオベンチャーです。2015年6月には東証マザーズに上場。再生・細胞医薬品の開発・製造を世界で先駆けて取り組み、病で苦しむ患者さんに治療法を提供し希望を届けることを目標としています。
Our company is a bio venture which is doing R & D of somatic stem cell regenerating medicine / iPSC regenerating medicine in the regenerative medicine field which is rapidly developing by the bio-revolution. We were listed on TSE Mothers in June 2015. Our long-term object is to deliver hope to patients suffering from illness by providing treatment methods by pioneering the development and manufacture of regeneration and cellular medicines worldwide.
Company Details
- Employees
- 29
- Founded
- -
- Address
- 2-4-1 Hamamatsucho, Minato-Ku,tokyo 105-6115,japan
- Phone
- 81 3 3544 8730
- in****@****apan.jp
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- healios.co.jp
- Keywords
- iPS, バイオベンチャー, MultiStem, Stem cell, 再生医療, 再生医薬品, マザーズ.
- HQ
- Minato-ku, Tokyo
株式会社ヘリオス Questions
株式会社ヘリオス's helpline number is 81 3 3544 8730
株式会社ヘリオス's website is healios.co.jp
株式会社ヘリオス's LinkedIn profile is https://jp.linkedin.com/company/healios-k-k-
株式会社ヘリオス has
29 employees.
View email and phone details for 29
employees at 株式会社ヘリオス.
株式会社ヘリオス's industry is
Biotechnology Research
株式会社ヘリオス's top competitors are
Wcc Biomedical 怡定興生醫,
Akron Bio,
Cytix Inc.,
Nomura Siam International Co., Ltd.,
Novoron Bioscience,
Ray Therapeutics, Inc.,
Saisei Ventures,
Powerx, Inc.,
Japan-Taiwan Biotech Association (Jtba) | 日本台灣生技協會,
Athersys.
株式会社ヘリオス's support email address is info@rijapan.jp
株式会社ヘリオス's categories are Biotechnology Research
株式会社ヘリオス's founding year is 2011
